Mary Willis, MD
Neurology · Cleveland, OHNPI 1710188248
Payments from drug & device makers
Across 307 payments — averaging $1724.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$186K
- Biogen$138K
- Novartis$133K
- E.r. Squibb & Sons, L.L.C.$31K
- Genentech USA, Inc.$23K
- EMD Serono, Inc.$3K
- plus $15K from 22 others
Across 9 payments — averaging $1705.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$14K
- Novartis$958
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 47 | $185,764 |
| Biogen | 87 | $138,460 |
| Novartis | 22 | $133,229 |
| E.r. Squibb & Sons, L.L.C. | 19 | $30,994 |
| Genentech USA, Inc. | 36 | $22,884 |
| EMD Serono, Inc. | 19 | $3,481 |
| Sanofi | 6 | $3,454 |
| Greenwich Biosciences, Inc. | 3 | $3,424 |
| Bristol Myers Squibb | 13 | $3,138 |
| Amgen(2 entities) | 13 | $2,689 |
| Genentech, Inc. | 2 | $1,226 |
| AbbVie(2 entities) | 9 | $164 |
| UCB, Inc. | 5 | $136 |
| Acadia Pharmaceuticals Inc | 6 | $104 |
| Johnson & Johnson | 4 | $63 |
| TG Therapeutics, Inc. | 2 | $53 |
| Sanofi-aventis U.S. LLC | 1 | $50 |
| MDD US Operations, LLC | 2 | $42 |
| CSL Behring | 1 | $35 |
| Teva Pharmaceuticals USA, Inc. | 2 | $33 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $24 |
| Lundbeck LLC | 1 | $22 |
| SK Life Science, Inc. | 1 | $21 |
| Catalyst Pharmaceuticals, Inc. | 1 | $21 |
| GE HealthCare | 1 | $17 |
| Eisai Inc. | 1 | $16 |
| Sunovion Pharmaceuticals Inc. | 1 | $16 |
| Kyowa Kirin, Inc. | 1 | $11 |
How this compares
$529,570 in reported general payments places this provider in the 90th percentile of 702 neurology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology in Cleveland
- Robert BermelCleveland$6.4M
- Jeffrey CohenCleveland$3.1M
- Yuebing LiCleveland$1.4M
- Devon ConwayCleveland$1.3M
- Robert FoxCleveland$1.3M
- Glen StevensCleveland$1.1M
- Hubert FernandezCleveland$1.1M
- Hesham AbboudCleveland$1.1M
- Michal GostkowskiCleveland$850K
- Daniel OntanedaCleveland$838K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.